PHILADELPHIA, Pennsylvania and REHOVOT Israel, January 16 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq: ROSG) and collaborators, today unveiled initial data relating to the company's colorectal cancer screening diagnostics test, miRscreen(TM) colon, which is based on a simple blood draw, and is expected to be released next year. The company's scientists and collaborators have identified microRNA biomarkers in serum, which have the potential to accurately differentiate colorectal cancer patients from healthy individuals. The data is being presented at the ASCO 2009 Gastrointestinal Cancers Symposium, in San Francisco.
"The initial data presented by Rosetta is very significant" said Aaron Ciechanover, Nobel laureate and chairman of Rosetta's scientific advisory board. "Rosetta's scientists and their collaborators, have for the first time, identified in serum, potential microRNA biomarkers of colorectal cancer. If treated early, 90% of colon cancer patients survive. The humane, medical, and financial impact of an effective, non-invasive colon cancer screening test can not be overstated."
Over 90 million Americans are at risk for colon cancer, a disease that kills 50,000 Americans every year.
The company, together with collaborators, has shown that two microRNA biomarkers, obtained from a simple blood draw, identified colon cancer patients from healthy individuals with 91% sensitivity and 72% specificity.
"Rosetta's underlying serum-microRNA platform is extremely sensitive, and has demonstrated detection sensitivity on the order of a single molecule, single nucleotide specificity, and up to 700 fold test-to-control increase of certain serum microRNA biomarkers." said Dr. Ayelet Chajut, EVP R&D Molecular Biology at Rosetta and the primary investigator of the study. "We expect our test will serve as an initial screening tool, that will encourage patients to undergo colonoscopy."
Last year, Rosetta made commercially available three microRNA-based cancer diagnostic tests that leverage microRNA's high specificity as biomarkers.
"Preventive medicine technologies such as Rosetta's, have the potential to play an important role in improving health and cutting healthcare costs," Said Ciechanover. "With routine screening and early detection so critical in fighting colon cancer, the medical and business significance of such a technology could be very substantial."
The data presented at the conference will be available for downloading from the company's website, at http://www.rosettagenomics.com as of Sunday January 18th morning.
 American Gastroenterological Association ( http://www.fdhn.org )
 'Serum MicroRNAs as Biomarkers', Gilad et. al., PloS ONE, Sep 2008
MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company's first three microRNA-based tests, miRview(TM) squamous, miRview(TM) mets, and miRview(TM) meso, are commercially available through its Philadelphia-based CLIA-certified lab. Rosetta Genomics is the 2008 winner of Wall Street Journal's Technology Innovation Awards in the medical/biotech category.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease, and the success and timing of the miRscreen(TM) colon diagnostic test, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic tools, which is unproven and may never lead to commercially accepted products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties and its ability to operate without infringing the proprietary rights of others; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop and commercialize its candidate tools, products and services; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
Contact: Media& Investors Ron Kamienchick T: +1-646-509-1893 E: firstname.lastname@example.org
|SOURCE Rosetta Genomics Ltd|
Copyright©2009 PR Newswire.
All rights reserved